The US Preventive Services Task Force (USPSTF) has issued updated guidelines definitively recommending against initiating daily low-dose aspirin therapy for the primary prevention of cardiovascular disease in adults aged 60 and older — a guidance that affects an estimated 29 million Americans currently taking aspirin without a prior heart attack or stroke.

The Evidence That Changed Everything

The reversal is driven by three landmark trials that together enrolled nearly 47,000 participants and consistently found that aspirin’s bleeding risks outweigh its cardiovascular benefits in older adults without established heart disease.

The ASPREE trial — which enrolled 19,114 healthy Australians and Americans aged 70 and older — found that daily 100mg aspirin did not reduce cardiovascular events compared to placebo but was associated with a 38% higher rate of major haemorrhage and a non-significant increase in all-cause mortality. A subsequent analysis showed that cancer deaths — particularly gastrointestinal cancer — were higher in the aspirin group, a finding that remains under investigation.

Who Should Still Take Aspirin

The new guidelines apply specifically to primary prevention — meaning adults who have never had a heart attack, stroke, or other atherosclerotic cardiovascular event. The recommendations do not apply to:

  • Adults with prior myocardial infarction or stroke — aspirin remains a cornerstone of secondary prevention
  • Adults with coronary stents — antiplatelet therapy is essential
  • Adults who have been taking aspirin for years without bleeding complications — stopping may itself carry risks; discuss with your doctor
  • Adults at very high cardiovascular risk aged 40–59 — the USPSTF gives this a Grade C recommendation (individualised decision)

“The decision to stop recommending aspirin for older adults was not taken lightly. The evidence is now unambiguous: in this population, aspirin causes more harm than it prevents.”

— Dr. Katrina Donahue, USPSTF Chair, University of North Carolina

Why This Took So Long

Aspirin’s cardiovascular protective effect was first established in secondary prevention trials in the 1970s and 1980s. For decades, cardiologists extrapolated these findings to primary prevention — a logical but ultimately incorrect assumption. The bleeding risk associated with aspirin increases substantially with age due to age-related changes in gastric mucosa integrity, platelet function, and renal clearance of the drug.

What To Do If You Currently Take Aspirin

Do not stop aspirin abruptly without consulting your doctor. Abrupt cessation in patients who have been on aspirin for extended periods may trigger a rebound prothrombotic effect. Your physician will assess your individual cardiovascular risk profile and bleeding history before making a recommendation.

If you are healthy and over 60 and have never had a cardiac event, the new guidance suggests that beginning aspirin now offers no net benefit and exposes you to meaningful bleeding risk.

⚕️ Medical Disclaimer: This article is for informational purposes only. It does not constitute medical advice. Always consult a qualified healthcare professional before making health decisions.